| Dr Esther T Dunn, M D | |
|
1913 Steele Rd, Alvin, TX 77511-5526 | |
| (281) 488-7213 | |
| (281) 824-8711 |
| Full Name | Dr Esther T Dunn |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 38 Years |
| Location | 1913 Steele Rd, Alvin, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548481070 | NPI | - | NPPES |
| 135299903 | Other | TX | CAIDBRAZORIA |
| 380054ZJOX | Other | TX | CAREBRAZORIA |
| 180023991 | Other | TX | RRCARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | H1953 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Coastal Eye Associates Pllc | 2264479112 | 14 |
News Archive
The Wall Street Journal profiles the case of a man infected with extensively drug-resistant tuberculosis (XDR-TB) who is being detained in South Texas after a "three-month odyssey through 13 countries - from his homeland of Nepal through South Asia, Brazil, Mexico, and finally into Texas - show[ing] the way in which dangerous new strains of the disease can migrate across the world unchecked."
Winston Pharmaceuticals, Inc. a specialty pharmaceutical company focused on developing and commercializing novel pain management therapies, announced the results of its Phase II study on its patented Dolorac Nasal Solution (doxepin 0.4%) for prophylaxis of chronic migraine at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.
A "vicious cycle" produces mucus that protects uterine and pancreatic cancer cells and promotes their proliferation, according to researchers at Rice University. The researchers offer hope for a therapeutic solution.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced it has received an offer for funding from a biotech-oriented investment group called BIOTECH Development Partners, LLC.
› Verified 1 days ago
| Entity Name | Coastal Eye Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922070036 PECOS PAC ID: 2264479112 Enrollment ID: O20050412000737 |
News Archive
The Wall Street Journal profiles the case of a man infected with extensively drug-resistant tuberculosis (XDR-TB) who is being detained in South Texas after a "three-month odyssey through 13 countries - from his homeland of Nepal through South Asia, Brazil, Mexico, and finally into Texas - show[ing] the way in which dangerous new strains of the disease can migrate across the world unchecked."
Winston Pharmaceuticals, Inc. a specialty pharmaceutical company focused on developing and commercializing novel pain management therapies, announced the results of its Phase II study on its patented Dolorac Nasal Solution (doxepin 0.4%) for prophylaxis of chronic migraine at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.
A "vicious cycle" produces mucus that protects uterine and pancreatic cancer cells and promotes their proliferation, according to researchers at Rice University. The researchers offer hope for a therapeutic solution.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced it has received an offer for funding from a biotech-oriented investment group called BIOTECH Development Partners, LLC.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Esther T Dunn, M D 555 E Medical Center Blvd, Suite 101, Webster, TX 77598-4367 Ph: (281) 488-7213 | Dr Esther T Dunn, M D 1913 Steele Rd, Alvin, TX 77511-5526 Ph: (281) 488-7213 |
News Archive
The Wall Street Journal profiles the case of a man infected with extensively drug-resistant tuberculosis (XDR-TB) who is being detained in South Texas after a "three-month odyssey through 13 countries - from his homeland of Nepal through South Asia, Brazil, Mexico, and finally into Texas - show[ing] the way in which dangerous new strains of the disease can migrate across the world unchecked."
Winston Pharmaceuticals, Inc. a specialty pharmaceutical company focused on developing and commercializing novel pain management therapies, announced the results of its Phase II study on its patented Dolorac Nasal Solution (doxepin 0.4%) for prophylaxis of chronic migraine at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.
A "vicious cycle" produces mucus that protects uterine and pancreatic cancer cells and promotes their proliferation, according to researchers at Rice University. The researchers offer hope for a therapeutic solution.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced it has received an offer for funding from a biotech-oriented investment group called BIOTECH Development Partners, LLC.
› Verified 1 days ago